



Scientific Program

(as of May 2023)

Wednesday, May 31, 2023

17h00 – 18h00 **General Assembly E-ISFA**
(by invitation only)

Thursday, June 1, 2023

08h30 – 08h55 **Opening Ceremony**
Chairs: Bernd Hohenstein, ISFA President (DE), Wolfgang Ramlow, E-ISFA President (DE)

Congress Opening by
Bernd Hohenstein, ISFA President (DE)
Wolfgang Ramlow, E-ISFA President (DE)
Ulrich Julius, Honorary Congress President E-ISFA (DE)
Horst Klinkmann, Honorary Congress President ISFA (DE)

09h00 – 10h20 **Apheresis around the world I:**
Country specific aspects

Chairs:
Shamanna Iyengar (Bangalore, IN)
Olivier Moranne (Nimes, FR)
▲ **Presentations ()**
Kurt Derfler (Institute ATHOS, Vienna, AT)
Organization and national activities of therapeutic apheresis in Austria

Lipid disorders and CVD I:
Lipid disorders – it all starts with the measurement

Chairs:
Patrick Moriarty (Kansas City, US)
Winfried März (Cologne, DE)
▲ **Presentations ()**
Winfried März (SYNLAB Akademie, DE)
Dyslipidemia – it all starts with a correct measurement

Ken Yamaji (Juntendo University, Tokyo, JP)
Organization and national activities of therapeutic apheresis in Japan

Amber Sanchez (University of California San Diego, US)
Organization and national activities of therapeutic apheresis in the USA

Selected from abstracts:

Nosakhare G. Bazuaye et al. (Igbinedion University Teaching Hospital, Benin, Nigeria)
Apheresis activities in a low resource country Nigeria: a five years report of a single center

10h20 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h05

Apheresis around the world II:
South East Asian perspectives

Chairs:

Sasitorn Siritho (Bangkok, TH)
Wolfgang Ramlow (Rostock, DE)

▲ **Presentations ()**

Sasitorn Siritho (Bumrungrad International Hospital, TH)
Systematic review of TPE practices in central neuroimmunological disorders: evolving concepts in South East Asia

Lu Fiong Hiew (Kuala Lumpur Hospital, MY)
Uniting the world through TPE: SEATPEC challenges & potential future collaborations

Nghia Hoang (Military Hospital, Ho Chi Minh, VN)
TPE and its challenges in Vietnam

Dhayalen Krishnan (Kuala Lumpur General Hospital, MY)
Introduction to SEATPEC, best practices and TPE guidelines in South East Asia

12h05 – 12h30

Coffee Break, Exhibition & Poster Viewing

12h30 – 13h45

Lunch Symposium
(<https://www.isfa2023.com/lunchsymposia/>)

Johanna Schachtl-Riess (Medical University of Innsbruck, AT)
Lipoprotein(a) – from genetics to phenotype

Jeffrey Kroon (University of Amsterdam, NL)
Evidence for a strong pro-inflammatory potential of lipoprotein(a)

Patrick Moriarty (University of Kansas Medical Center, Kansas City, US)
Lipoprotein-apheresis and its effect on HDL functionality

Registries

Registries as research tools in apheresis

Chairs:

Ulrich Julius (Dresden, DE)
Volker Schettler (Goettingen, DE)

▲ **Presentations ()**

Christian Schumann (MVZ Kempten, DE)
CACOV – an apheresis registry for severely ill acute COVID patients

Bernd Hohenstein (Nephrologisches Zentrum Villingen-Schwenningen, DE)
The German Long-Covid Apheresis Register – design and first experiences

Wanja Bernhardt (Centre for Hypertension, Kidney and Metabolic diseases, Hanover, DE)
The German Lipoprotein Apheresis Register – a specific analysis of Lp(a) apheresis patients

Selected from abstracts:

Phandee Watanaboonyongcharoen et al. (Chulalongkorn University, Bangkok, TH)
A multicenter study of safety and incidence of adverse reactions associated with therapeutic apheresis in Thai patients

Lunch Symposium
(<https://www.isfa2023.com/lunchsymposia/>)

Apherese-Weiterbildung in deutscher Sprache:
Teil 1

▲ **Program part 1 ()**

Jens Ringel (Potsdam, DE)
Begrüßung

N. N.
Apherese, eine erfolgreiche Geschichte

Uwe H. Wallstab (Wernigerode, DE)
Apherese ist nicht gleich Apherese

13h45 – 14h00

Break

14h00 – 15h15

Apheresis around the world III:

Current updates & issues (from the American Society for Apheresis – ASFA)

Chair:

Bernd Hohenstein (Villingen-Schwenningen, DE)

▲ Presentations ()

Joseph (Yossi) Schwartz (Moffit Cancer Center, Florida, US)

Growing variations in collections for further manufacturing

Betty Doggett (Carter BloodCare, Laird Hill, US)

Vascular access – issues & resolutions

Nicole Aqvi (Perelman School of Medicine, University of Pennsylvania, US)

ASFA Guidelines for Therapeutic Apheresis – 2023

15h15 – 15h45

Coffee Break & Poster Viewing

15h45 – 17h30

Apheresis around the world IV

Apheresis therapy in Japan – JSFA Workshop

Chairs:

Ken Yamaji (Tokyo, JP)

Wolfgang Ramlow (Rostock, DE)

▲ Presentations ()

Ken Yamaj (Juntendo University, Tokyo, JP)

Updated Topics in PE, DFPP and plasma adsorption using the membrane separation

Shuzo Kobayashi (Shonan Kamakura General Hospital, Kanagawa, JP)

A novel LDL/fibrinogen apheresis 'Rheocarna' for patients with chronic limb-threatening ischemia

Autoimmune diseases I

Neuroimmune diseases and immunomodulation

Chairs:

Dhayalen Krishnan (Kuala Lumpur, MY)

Reinhard Klingel (Cologne, DE)

▲ Presentations ()

Wolfgang Köhler (Leipzig University, DE)

The role of apheresis therapy in MS and NMOSD

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)

Immunomodulatory effect associated with therapeutic plasmapheresis

Selected from abstracts:

Miriam Lanska et al. (University Hospital and Faculty of Medicine, Hradec Kralove, CZ)

Efficacy and safety of long-term immunoabsorption therapy in patients with myasthenia gravis

Selected from abstracts:

Virginia Athanasiadou et al. (National and Kapodistrian University of Athens, GR)

Therapeutic Plasmapheresis: A safe and effective periodic treatment for chronic inflammatory demyelinating polyneuropathy

Apheresis in critical care medicine**Chairs:**

Wladimir Szpirt (Copenhagen, DK)

Jan Kielstein (Braunschweig, DE)

▲ Presentations ()

Jan Stange (University Medical Center Rostock, DE)

Recent developments in the field of extracorporeal albumin detoxification (ECAD) for liver support

Gerd Klinkmann (University Medical Center Rostock, Department of Anesthesiology and Intensive Care Medicine, DE)

Extracorporeal immune cell therapy in sepsis

Apherese-Weiterbildung in deutscher Sprache:

Teil 2

(14h00 – 15h30)

▲ Programm Teil 2 ()

Jens Ringel (Potsdam, DE)

Ultima ratio bei Lipoproteinstörungen

N.N.

Apherese mehr als nur Lipidreduktion

Jörg Müller (Dresden, DE)

Heparin oder Citrat zur Antikoagulation

Apherese-Weiterbildung in deutscher Sprache:

Teil 3

(16h00 – 17h45)

▲ Programm Teil 3 ()

Schwester Anja Ramlow (Rostock, DE)

Pflegerische Aspekte in der Apheresebehandlung von Long/Post-Covid Patienten

Volker Witt (Vienna, AT)

Pflegerische Aspekte in der Apheresebehandlung von Kindern

Tomoki Tanaka (Shiga University, Shiga, JP)
The development history of Toraymyxin and the update of clinical data of PMX-DHP

Makoto Naganuma (Kansai Medical University, Osaka, JP)
Developments and future perspective of apheresis therapy for inflammatory bowel disease

Steffen Mitzner (University Medical Center Rostock, DE)
Cytokine adsorption in sepsis and septic shock – still under debate

Amber Sanchez (University of California San Diego, US)
How to combine multiple extracorporeal systems in critical care

Sascha David (Zurich University Hospital, CH)
TPE in septic shock: to remove and replace

Jens Ringel (Potsdam, DE)
Vorstellung der E-ISFA

Jens Ringel (Potsdam, DE)
Verabschiedung

17h30 – 19h30

Welcome Reception & Poster Session

Friday, June 2, 2023

08h30 – 09h50

Apheresis around the world V:
Country specific aspects

Chairs:

Amber Sanchez (San Diego, US)
Kurt Derfler (Vienna, AT)

▲ Presentations ()

Shamanna Iyengar (Manipal Academy of Higher Education, IN)
On the way to establish a lipid apheresis program in India by Lipid Association of India (LAI)

Ahmad AlSaraf (Sabah AlAhmad Cardiac Center, KW)
LDL apheresis in homozygous familial hypercholesterolemia in Kuwait

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)
Cross sectional analysis of apheretical therapies in Italy

Olivier Moranne (CHU Caremeau Nimes, University Montpellier, FR)
Organization and national activities of therapeutic apheresis in France

09h50 – 10h20

Coffee Break, Exhibition & Poster Viewing

10h20 – 12h10

COVID-19 I:
Apheresis in COVID-19 and its complications

Guest workshop:

Association of German Dialysis Centers (DN e. V.)

Chairs:

Georg Schlieper (Hanover, DE)
Wladimir Szpirt (Copenhagen, DK)

▲ Presentations ()

Georg Schlieper (Dialysis Centre Hanover, DE)
Is there a role for immunoadsorption in Post Covid?

Volker Schettler (Center of Nephrology, Dialysis and Apheresis, Göttingen, DE)
The German Lipoprotein Apheresis Registry (GLAR) – Summary of the tenth annual report

Jan Kielstein (Braunschweig Hospital, DE)
From sepsis to COVID – apheresis therapy in critical care medicine

Lipid disorders and CVD II:
Apheresis targeting microcirculation and inflammation

09h00 – 12h00

Apherese-Weiterbildung in deutscher Sprache:

▲ Anwenderworkshop Teil 1 ()

Jens Ringel (Potsdam, DE)
Schwester Anja Ramlow (Rostock, DE)
Begrüßung

Gruppenarbeit an den verschiedenen Maschinen mit Erfahrungsaustausch unter den Pflegenden zu je 150 min
(<https://www.isfa2023.com/apherese-weiterbildung/>)
(unter Beteiligung der Medizinprodukte-Hersteller)
(_wp_link_placeholder)

Chairs:

Julia Weinmann-Menke (Mainz, DE)
 Bernd Hohenstein (Villingen-Schwenningen, DE)
▲ Presentations ()

Carmen Scheibenbogen (Charité –

Universitätsmedizin Berlin, DE)
Long-term consequences of COVID and current therapeutic perspectives

Beate Jäger (DE)

Long COVID – why apheresis therapy could make the difference

Harald Matthes (Havelhöhe Community Hospital, Berlin, DE)

Is apheresis therapy an option for neuroinflammatory Post-vaccination syndrome?

Panel discussion – pro and contra

12h10 – 12h30

Lunch Break, Exhibition & Poster Viewing

12h30 – 13h45

Lunch Symposium
 (<https://www.isfa2023.com/lunchsymposia/>)

13h45 – 14h00

Lunch Break, Exhibition & Poster Viewing

14h00 – 15h20

COVID-19 II:

Treatment approaches in COVID and its consequences

Chairs:

Yoshihiro Endo (Otsu, Shiga, JP)
 Steffen Mitzner (Rostock, DE)

▲ Presentations ()

Wladimir M. Szpirt (Rigshospitalet, Copenhagen, DK)

Plasma exchange utilizing convalescent plasma in severe COVID patients

New guidelines and developments:

Technical regulations and developments

Chairs:

Victoria Weber (Krems, AT)
 Andre Kaplan (Plainville, US)

▲ Presentations ()

Uwe H. Wallstab (mdXperts GmbH, Cologne, DE)

Relevance of sufficient clinical safety and performance data to maintain CE mark of apheresis devices

Chairs:

Luigi Vernaglione (Brindisi, IT)
 Wanja Bernhardt (Hanover, DE)
▲ Presentations ()

Luigi Vernaglione (Perrino Hospital, Brindisi, IT)

Apheresis to improve rheology – indications and results

Dusit Lumlertgul (Faculty of Medicine, Chiang Mai, TH)

Double filtration plasmapheresis (DFPP) to improve microcirculation

Jan Torzewski (Allgäu Hospital Network, Immenstadt, DE)

CRP – from laboratory parameter to key player of inflammation

Selected from abstracts:

Rosita Bihariesingh et al. (Academic Hospital Paramaribo Suriname)

First-in-Man: Plasmapheresis with a novel blood separation device in hypertriglyceridemia and acute pancreatitis

Selected from abstracts:

Mohamed Sedky et al. (Kuwait Central Blood Bank)

A fifteen-years analysis of therapeutic apheresis practices in state of Kuwait

Lipid disorders and CVD III:

Workshop German Lipid League

Chairs:

Oliver Weingärtner (Jena, DE)
 Volker Schettler (Goettingen, DE)

▲ Presentations ()

Oliver Weingärtner (University Hospital Jena, DE)
A nationwide initiative to reach lipid targets

13h00 – 15h30

Apherese-Weiterbildung in deutscher Sprache:

► Anwenderworkshop Teil 2 ()

Sebastian Koball (University Medical Center Rostock, DE)
How to evaluate apheresis efficacy in patients suffering from Long COVID?

Gunnar Bücker (Nephrology group practice, Osnabrück, DE)
First clinical results after HELP apheresis in Long COVID Syndrome

Julia Weinmann-Menke (Universitätsmedizin Mainz, DE)
Removal of circulating antibodies to adenoassociated virus vectors by immunoadsorption

Viktoria Weber (Danube University Krems, AT)
Influence of the column surface on therapeutic apheresis – an old issue but new developments are rising

Selected from abstracts:
Andrew Aswani et al. (Santerus AG, CH)
Safety and performance of the NucleoCapture®Column for selective cfDNA/NETs apheresis in patients with sepsis

Selected from abstracts:
Kensuke Owari et al. (TAGCyx Biotechnologies, Inc., Tokyo, JP)
Development of next generation apheresis using artificial base DNA Aptamer

Anja Vogt (Ludwig Maximilians University Hospital, Munich, DE)
Novel lipid lowering medications – current status and future perspectives

Ulrich Julius (University Hospital Dresden, DE)
Cardiovascular events before and during apheresis treatment – a detailed analysis for vascular regions

15h20 – 15h45

Coffee Break, Exhibition & Poster Viewing

15h45 – 17h30

Lipid disorders and CVD IV:
Treatment modalities in clinical practice

Chairs:
Mariko Harada-Shiba (Osaka, JP)
Tiziana Sampietro (Pisa, IT)

▲ Presentations ()

Wanja Bernhardt (Dialysis Centre Hanover, DE)
Long-term experience of Lp(a) apheresis in outpatient care

Tiziana Sampietro (National Research Council Institute of Clinical Physiology, Pisa, IT)
The role of lipoprotein apheresis on hypercholesterolemia and Lp(a) – the Pisa experience

Ulrich Julius (University Hospital Dresden, DE)
Comparison of the plasma lipoprotein apheresis systems MONET and Lipidfiltration from Diamed vs. the whole blood apheresis system DALI in the treatment of patients with cardiovascular disease and severe dyslipidemia

Autoimmune diseases II:
Apheresis in rheumatologic and inflammatory bowel disease

Chairs:
Ken Yamaji (Tokyo, JP)
Harald Matthes (Berlin, DE)

▲ Presentations ()

Andreas Kronbichler (Medical University Innsbruck, AT)
Apheresis therapy in autoimmune vasculitides – PEXIVAS is not the end

Yoshihiro Endo (Shiga University of Medical Science, Otsu, JP)
Novel hemo-adsorbent for ulcerative colitis in Japan

Makoto Naganuma (Keio University School of Medicine, Tokyo, JP)
Recent trends of apheresis treatment for inflammatory bowel disease

Ken Yamaji (Juntendo University, Tokyo, JP)
Is apheresis therapy still an option in rheumatic diseases?

Apheresis Service and Education
(in English language)

Chairs:
Betty Doggett (Laird Hill, US)
N. N.

► Speakers ()

Janneke Mulder (NL)*Quality of life in Dutch hoFH patients***Mariko Harada-Shiba** (National Cerebral and Cardiovascular Center, Osaka, JP)*Development of novel drug for primary chylomicronemia by using antisense*

Selected from abstracts:

Natalia Jarzebska (University Hospital Dresden)*Apheresis treatment leads to increased levels of circulating neutrophil extracellular traps*

18h30 – 23h00

Congress Dinner

Saturday, June 3, 2023

08h30 – 10h15

Autoimmune diseases III

Apheresis for renal diseases

Chairs:

Andreas Kronbichler (Innsbruck, AT)

Wladimir Szpirt (Copenhagen, DK)

▲ Presentations ()**Lionel Rostaing** (CHU Grenoble Alpes, Grenoble, FR)*Apheresis and desensitization before kidney transplantation***Benjamin Savenkoff** (CHR Metz-Thionville, FR)*The role of apheresis therapy in glomerulopathies***Vladimir Kuklin (Bruggemann)** (Ahus University Hospital, Lorenskog, NO)*Influence of therapeutic plasma exchange treatment on early survival of septic patients: a systematic review and meta-analysis***Wladimir Szpirt** (Rigshospitalet, Copenhagen, DK)*An evolution in treatment of anti GBM nephritis – plasma exchange or imlifidase?*

Selected from abstracts:

Haruna Yoshida et al. (Osaka City General Hospital)*Selective plasma exchange in critical care*

Selected from abstracts:

Noemi Elisabeth Ginthör et al. (Medical University of Graz, AT)*Evaluation of iron deficiency and mechanisms of potential iron loss in patients undergoing immunoabsorption***Lipids and CVD V:**

Pleiotropic and other expected windfall gains

Chairs:

Dursit Lumlertgul (Chiang Mai, TH)

N. N.

▲ Presentations ()**Grit Waitz** (BioArtProducts, Rostock, DE)*Cardiometabolic risk assessment – the impact of comorbidities***Mariko Harada-Shiba** (National Cerebral and Cardiovascular Center, Osaka, JP)*Lipoprotein apheresis for the treatment of familial hypercholesterolemia in Japan***Takafumi Ito** (JP)*Efficacy and safety of LDL apheresis for the treatment of cholesterol crystal embolism*

Selected from abstracts:

Lena Jochheim et al. (University Hospital Dresden, DE)*Actual situation at the Dresden Lipoprotein Apheresis in 2023*

Selected from abstracts:

Volker Schettler et al. (German Center for Neurodegenerative Diseases (DZNE) Goettingen, DE)*Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: exosomes pheresis*

Selected from abstracts:

Romy Walther (University Hospital Dresden, DE)*Prognostic value of plasma lipidome for determining the risk of cardiovascular events in patients with lipoprotein apheresis*

10h15 – 10h45

Coffee Break, Exhibition & Poster Viewing

10h45 – 12h30

Future perspectives of apheresis therapy

The future perspectives of apheresis

Chairs:

Bernd Hohenstein (Villingen-Schwenningen, DE)

Wolfgang Ramlow (Rostock, DE)

▲ Presentations ()**Patrick Moriarty** (University of Kansas Medical Center, Kansas City, US)*Future perspectives in apheresis therapy – lipoprotein apheresis***Jan Kielstein** (Braunschweig Hospital, DE)*Future perspectives in apheresis therapy – critical care medicine***Lionel Rostaing** (CHU Grenoble Alpes, Grenoble, FR)*Future perspectives in apheresis therapy – renal diseases and transplantation***Reinhard Klingel** (Apheresis Research Institute, Cologne, DE)*Future perspectives in apheresis therapy – immune-mediated conditions*

12h30 – 13h00

Closing Ceremony & Awards Presentation

13h00

Farewell**Pediatric apheresis**

Apheresis in children and adolescent patients

Chairs:

Julia Thumfart (Berlin, DE)

Volker Witt (Vienna, AT)

▲ Presentations ()**Wolfgang Ries** (Diako Hospital Flensburg, DE)*Severe chronic fatigue syndrome (ME/CFS) in children – when is immunoadsorption justified?***Julia Thumfart** (Charité – Universitätsmedizin Berlin, DE)*Apheresis therapy for pediatric neurological diseases – a German perspective***Volker Witt** (Paediatric Hospital “St. Anna”, Vienna, AT)*ECP in children and young adults – special needs*

Selected from abstracts:

Claudia Ootjers et al. (Leiden University Medical Centre)*Erythrocytapheresis prior to allogeneic stem cell transplantation in children with sickle cell disease is a safe and efficient method to lower sickle haemoglobin***Panel discussion:**

Particularities in pediatric apheresis



Kofinanziert von der Europäischen Union

This project is co-financed by the European Regional Development Fund (ERDF).

Newsletter

ISFA 2023 Newsletter:

Subscribe

After subscribing you will receive an email to confirm your subscription. Please also check the spam folder.

Important Dates

March 31, 2023

Extended Abstract Submission Deadline

March 31, 2023

Deadline Early Registration Fee

May 25, 2023

Deadline Standard Registration Fee

June 1 - 3, 2023

Joint ISFA - E-ISFA Congress in Berlin

Certifications



COMPLIANT

Submitted for certification to the Berlin State Medical Association

Certifications

Organizer

International Society for Apheresis – European Group

Schliemannstr. 2
18059 Rostock, Germany

✉ info@e-isfa.eu(mailto:info@e-isfa.eu)

🌐 www.e-isfa.eu(https://www.e-isfa.eu)



Congress Office

K.I.T. Group GmbH Dresden

Anja Binning
Bautzner Str. 117–119
01099 Dresden, Germany

☎ +49 351 65573135

✉ info@isfa2023.com(mailto:info@isfa2023.com)

🌐 www.kit-group.org(https://www.kit-group.org)



International Society For Apheresis




ISFA Headquarters

Shiga University of Medical Science
Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan

✉ isfa@belle.shiga-med.ac.jp(mailto:isfa@belle.shiga-med.ac.jp)

🌐 www.e-isfa.org(https://www.e-isfa.org/)



📄 [Imprint](https://www.isfa2023.com/imprint/)(https://www.isfa2023.com/imprint/)  [Disclaimer](https://www.isfa2023.com/disclaimer/)(https://www.isfa2023.com/disclaimer/)  [Privacy Statement](https://www.isfa2023.com/privacy-statement/)(https://www.isfa2023.com/privacy-statement/)
© 2022 K.I.T. Group GmbH Dresden(<https://www.kit-group.org>)  [Photo Credits](https://www.isfa2023.com/photo-credits/)(https://www.isfa2023.com/photo-credits/)